Is KYNTRA BIO, INC. (KYNB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 264.1% / 30% | 182.4% / 30% | 104.7% / 30% | 17.88% / 5% | ✗ NOT HALAL |
| DJIM | 264.1% / 33% | 182.4% / 33% | 104.7% / 33% | 17.88% / 5% | ✗ NOT HALAL |
| MSCI | 34.1% / 33% | 23.5% / 33% | 13.5% / 33% | 17.88% / 5% | ✗ NOT HALAL |
| S&P | 264.1% / 33% | 182.4% / 33% | 104.7% / 33% | 17.88% / 5% | ✗ NOT HALAL |
| FTSE | 34.1% / 33% | 23.5% / 33% | 13.5% / 50% | 17.88% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -273.8% | |
| Operating Margin | -1058.7% | |
| Net Margin | 2848.6% | |
| Return on Assets (ROA) | -17.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$5M |
| Free Cash Flow | -$5M |
| Debt-to-Equity | 437.1 |
| Current Ratio | 3.4 |
| Total Assets | $120M |
Price & Trading
| Last Close | $6.54 |
| 50-Day MA | $7.62 |
| 200-Day MA | $8.84 |
| Avg Volume | 33K |
| Beta | 0.9 |
|
52-Week Range
$4.85
| |
About KYNTRA BIO, INC. (KYNB)
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is KYNTRA BIO, INC. (KYNB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), KYNTRA BIO, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is KYNTRA BIO, INC.'s debt ratio?
KYNTRA BIO, INC.'s debt ratio is 264.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 34.1%.
What are KYNTRA BIO, INC.'s key financial metrics?
KYNTRA BIO, INC. has a market capitalization of $27M, and revenue of $6M. The company maintains a gross margin of -273.8% and a net margin of 2848.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.